Ratings Thai Coconut Co.,Ltd.

Equities

End-of-day quote Thailand S.E. Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
13.3 ^THB	+0.76%		+4.72%	+68.35%

04/04	Thai Coconut Public Company Limited Approves the Election of Miss Nidaporn Assawateerakiat as Independent Director, the Member of Audit Committee, the Member of Nomination and Compensation Committee, and the Member of Risk Management Committee	CI
04/04	Thai Coconut Public Company Limited Approves Dividend Payment for the Year 2023, Payable on May 2, 2024	CI

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
THAI COCONUT CO.,LTD.	+68.35%	53Cr		-
CHONGQING FULING ZHACAI GROUP CO., LTD.	-3.64%	219.24Cr		C
AGRANA BETEILIGUNGS-AG	-3.55%	92Cr		B-
LASSONDE INDUSTRIES INC.	+1.61%	71Cr	-	D
LONTRUE CO., LTD.	+18.17%	46Cr	-	-
CALAVO GROWERS, INC.	-13.74%	45Cr		C+
TIANYUN INTERNATIONAL HOLDINGS LIMITED	-3.03%	40Cr	-	-
TUKAS GIDA SANAYI VE TICARET	+16.25%	36Cr	-	-
BONDUELLE	-29.07%	27Cr		B
CHALKIS HEALTH INDUSTRY CO., LTD	-32.39%	26Cr	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality